Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ai Cure Technologies

Explore full profile

Uses Artificial Intelligence to visually confirm medication ingestion. Connecting the world's patients to better treatment and improved health

Houston, United StatesFounded 2010Health Tech & Medtech
Valuation $100–250M Last recorded · 2024
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Ai Cure Technologies and the history behind them.

About Ai Cure Technologies

AiCure is a cutting-edge startup that leverages artificial intelligence (AI) to enhance patient care and clinical research. The company has developed an innovative platform called IMA (Interactive Medical Assistant), which uses AI to monitor and understand patient responses to treatments. By utilizing visual and audio data, IMA can provide meaningful clinical insights, helping healthcare providers and researchers determine if treatments are effective.

AiCure primarily serves pharmaceutical companies, healthcare providers, and clinical researchers. These clients benefit from AiCure's ability to ensure patient adherence to prescribed treatments, improve retention rates in clinical trials, and detect any deceptive behaviors that might skew research results. The platform also identifies digital biomarkers, which are measurable indicators of a biological state or condition, to predict clinical progress more accurately.

Operating in the healthcare and pharmaceutical markets, AiCure addresses a critical need for reliable and real-time patient data. The company's business model revolves around offering its AI-driven platform as a service to its clients. AiCure generates revenue through subscription fees, licensing agreements, and possibly through data analytics services provided to its clients.

By confirming and optimizing patient behavior, AiCure's technology reduces the risk in clinical research and enhances the quality of patient care. This not only unlocks the potential for new therapies but also ensures that all patients receive the most effective treatments tailored to their unique responses.

In summary, AiCure is revolutionizing the way we understand and manage patient treatment through its AI-powered platform, IMA. The company stands at the intersection of healthcare and technology, providing invaluable insights that drive better clinical outcomes.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2010
Headquarters
Houston, United States
Employees
39
Open positions
None listed
Dealroom signal
62.9/100
Industry
Health
Sub-industry
Medical Devices, Health Platform
Sector
Health Tech & Medtech, Medication Adherence, Risk Management, Drug Development, Patient Care, Core AI, Facial Recognition, Clinical Trials, Tech for Biotech and Pharma, Hard Tech, AI Applications, DT and LS

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Jan 2024 $12M — Undisclosed ↗
LATE VCOther financing Jan 2024 $4M $123M Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Ai Cure Technologies website traffic

Latest recorded traffic for Ai Cure Technologies is 4.6K monthly website visits, up 15% over the last three months. Ai Cure Technologies's team declined 11.4% over the past year.

Latest monthly visits4.6K 3-month web change+15% 1-year team growth-11.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • US Department of Health and Human Services

Series A6 investors entered at this stage

  • Pritzker Group Venture Capital
  • New Leaf Venture Partners
  • Tribeca Venture Partners
  • Biomatics Capital Partners
  • Robert W. Baird & Co.
  • Baird Capital

Series B and later4 investors entered at this stage

Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States86.2%
🇨🇳 China6.9%
🇬🇧 United Kingdom3.5%
🇵🇰 Pakistan3.5%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ai Cure Technologies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ai Cure Technologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.